SecBot SecBot
8-K ·Filed Jun 8, 2026

NRIX

Nurix Therapeutics, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago SEC0001549595-26-000030
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

This is a transformative monetization of Nurix's lead asset that provides a massive cash infusion and validates the BTK degrader platform. The deal significantly reduces financing risk and funds an expanded pipeline through multiple value-creating catalysts. The stock should re-rate higher on the upfront cash, reduced dilution risk, and the credibility of a Roche partnership. Monitor for HSR clearance timing and any Phase 2 data readouts in MS/CSU as incremental catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$15.64
T+0 close · Jun 8, 2026 · via day close
Latest settled
+53.71%
T+20 · $24.04
Vs SPY
+52.08%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · Jun 8 $15.64entry
  2. T+1 · 5mo ago 0.00%α +0.29% · $15.64
  3. T+5 · 5mo ago +8.95%α +6.84% · $17.04
  4. T+20 · 4mo ago +53.71%α +52.08% · $24.04
  5. T+60 · due 3mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develop and co-commercialize bexobrutideg, a potential best-in-class BTK degrader, across oncology, immunology, and neurology. Roche will make an upfront cash payment of $700 million, with total potential payments up to $2.3 billion including milestones, and development costs will be split 40/60 (Nurix/Roche) with a 50/50 U.S. profit share and tiered ex-U.S. royalties. This deal provides significant non-dilutive capital, validates the asset's potential, and accelerates Nurix's path to becoming a fully integrated biopharma, making this a transformative event for the company.

Key Financial Metrics

Deal Value
$2.3B
Deal Type
partnership

Key Facts

  • Roche to pay $700 million upfront cash to Nurix for exclusive worldwide license to bexobrutideg (NX-5948), an oral BTK degrader.
  • Total potential payments to Nurix of up to $2.3 billion including development, regulatory, and sales milestones.
  • Nurix and Roche will co-develop and co-commercialize in the U.S. with a 50/50 profit/loss split; Roche leads ex-U.S. commercialization with tiered royalties (low-to-high teens).
  • Global development costs shared 40% by Nurix and 60% by Roche.
  • Clinical development plan includes Phase 2/3 trials in CLL and expansion into multiple sclerosis (MS) and chronic spontaneous urticaria (CSU) with planned Phase 2 trials.
  • Nurix reported a pro-forma cash balance of ~$1.24 billion after the upfront payment, extending its cash runway significantly.
  • Collaboration covers malignant hematology, immunology, and neurology targeting a combined addressable market of ~$48 billion projected for 2030.
  • Nurix retains 50/50 U.S. profit share and co-promotion rights, accelerating its evolution into a fully integrated biopharmaceutical company.
  • Deal is subject to HSR Act waiting period expiration and other antitrust clearance.
  • Goldman Sachs acted as exclusive financial advisor to Nurix.

Financial Impact

Nurix receives $700 million upfront in cash, with potential total milestone payments of up to $2.3 billion. Pro-forma cash balance climbs to approximately $1.24 billion, eliminating near-term funding risk and funding 40% of global development costs.

cash_balancerevenueoperating_expensesdilution

Risk Factors

  • Deal completion is contingent on HSR Antitrust Act waiting period expiration; delays or conditions could impact timing.
  • Clinical and regulatory risks remain; bexobrutideg is still investigational and may face safety/efficacy hurdles.
  • Nurix bears 40% of development costs, which could pressure cash if trials are more expensive than anticipated or if milestones are delayed.
  • Co-commercialization complexity in the U.S. could create operational challenges and misaligned incentives.
  • Competition from existing BTK inhibitors and other degraders could limit market share.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
96% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001549595-26-000030
Exhibit: ex992_nurixpresentation2.htm0001549595-26-000030
Exhibit: ex991_nurixpressrelease202.htm0001549595-26-000030
Document: 0001549595-26-000030-index-headers.html0001549595-26-000030
Document: 0001549595-26-000030-index.html0001549595-26-000030
Document: 0001549595-26-000030.txt0001549595-26-000030

Track record

33 reports on NRIX

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +53.71% at T+20 after the Jun 8, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.17 Now $14.73 −2.90% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.41 Now $14.73 −4.41% settles Dec 15
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  5. Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  6. Nov 4, 202612d ago 144 Neutral 2/10 Entry $14.84 Now $14.73 −0.74% settles Dec 4
  7. Nov 3, 202613d ago 144 Neutral 2/10 Entry $15.95 Now $14.73 −7.65% settles Dec 3
  8. Nov 3, 202613d ago 8-K Bearish 5/10 Entry $15.95 Now $14.73 +7.65% settles Dec 3
  9. Nov 2, 202614d ago Insider Cluster Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $25.82 Now $14.73 −42.95% settles Dec 2
Showing 10 of 33

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026